These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 4208914)

  • 1. The relationship between PF-DIL and activated human Hageman factor.
    Johnston AR; Cochrane CG; Revak SD
    J Immunol; 1974 Jul; 113(1):103-9. PubMed ID: 4208914
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammatory process in acute gouty arthritis. 3. Vascular permeability-enhancing activity in normal human synovial fluid; induction by Hageman factor activators; and inhibition by Hageman factor antiserum.
    Kellermeyer RW
    J Lab Clin Med; 1967 Sep; 70(3):372-83. PubMed ID: 6038543
    [No Abstract]   [Full Text] [Related]  

  • 3. Isolation of prekallikrein activator from guinea pig serum or plasma adsorbed to immune precipitates or celite: possible relationship to Hageman factor.
    Treloar MP; Pyle H; Ozge-Anwar AH; Takeuchi Y; Movat HZ
    Eur J Immunol; 1972 Aug; 2(4):338-45. PubMed ID: 5083514
    [No Abstract]   [Full Text] [Related]  

  • 4. Abolition of the permeability-enhancing properties of Hageman factor by specific antiserum.
    Kellermeyer RW; Ratnoff OD
    J Lab Clin Med; 1967 Sep; 70(3):365-71. PubMed ID: 4166883
    [No Abstract]   [Full Text] [Related]  

  • 5. Guinea pig Hageman factor as a vascular permeability enhancement factor.
    Yamamoto T; Cochrane CG
    Am J Pathol; 1981 Nov; 105(2):164-75. PubMed ID: 6794374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular permeability factors (PF/Nat and PF/Dil)--their relationship to Hageman factor and the kallikrein-kinin system.
    Oishi S; Webster ME
    Biochem Pharmacol; 1975 Mar; 24(5):591-8. PubMed ID: 235929
    [No Abstract]   [Full Text] [Related]  

  • 7. [Promotion mechanism of vascular permeability by Hageman factor].
    Yamamoto T
    Rinsho Byori; 1982 Jun; Suppl 50():114-26. PubMed ID: 7131802
    [No Abstract]   [Full Text] [Related]  

  • 8. LARGE MOLECULAR SUBSTANCES AS MEDIATORS OF THE INFLAMMATORY REACTION.
    MILES AA
    Ann N Y Acad Sci; 1964 Aug; 116():855-65. PubMed ID: 14212858
    [No Abstract]   [Full Text] [Related]  

  • 9. A direct enzymatic assay for the esterolytic activity of activated Hageman factor.
    Ulevitch RJ; Letchford D; Cochrane CG
    Thromb Diath Haemorrh; 1974 Mar; 31(1):30-9. PubMed ID: 4857887
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of oxyphenbutazone on partial thromboplastin time and lack of effect on Hageman factor in guinea pigs.
    Weiner M
    J Med; 1971; 2(2):120-5. PubMed ID: 5286513
    [No Abstract]   [Full Text] [Related]  

  • 11. The interaction of Hageman factor and immune complexes.
    Cochrane CG; Wuepper KD; Aiken BS; Revak SD; Spiegelberg HL
    J Clin Invest; 1972 Oct; 51(10):2736-45. PubMed ID: 5056666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protease-like permeability factor in guinea pig skin: immunologic identity with plasma Hageman factor.
    Yamamoto T; Cochrane CG
    Am J Pathol; 1982 May; 107(2):127-34. PubMed ID: 7044129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic demonstration of a deficiency of Hageman factor-like material in Hageman trait.
    Smink MM; Daniel TM; Ratnoff OD; Stavitsky AB
    J Lab Clin Med; 1967 May; 69(5):819-32. PubMed ID: 4960805
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoquantitation of Hageman factor in urine and plasma of children with nephrotic syndrome.
    Hruby MA; Honig GR; Shapira E
    J Lab Clin Med; 1980 Sep; 96(3):501-10. PubMed ID: 6772722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guinea pig macroalbumin. A major inhibitor of activated Hageman factor in plasma with an alpha 2-macroglobulin-like nature.
    Ishimatsu T; Yamamoto T; Kozono K; Kambara T
    Am J Pathol; 1984 Apr; 115(1):57-69. PubMed ID: 6201075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q.
    Volanakis JE; Kaplan MH
    J Immunol; 1974 Jul; 113(1):9-17. PubMed ID: 4208926
    [No Abstract]   [Full Text] [Related]  

  • 17. THE PRESENCE OF TWO PERMEABILITY GLOBULINS IN HUMAN SERUM.
    KAGEN LJ; LEDDY JP; BECKER EL
    J Clin Invest; 1963 Aug; 42(8):1353-61. PubMed ID: 14057861
    [No Abstract]   [Full Text] [Related]  

  • 18. PRESENCE OF KALLIKREIN IN THE GAMMA-GLOBULIN PERMEABILITY FACTOR OF GUINEA-PIG SERUM.
    DAVIES GE; LOWE JS
    Br J Pharmacol Chemother; 1963 Dec; 21(3):491-9. PubMed ID: 14110749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies in Down's syndrome. IV. Investigations on the "Xh" factor.
    Rittner C; Rittner B
    Clin Genet; 1973; 4(5):407-9. PubMed ID: 4270856
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunogenicity and specificity of collagen. XII. Demonstration by immunofluorescence and haemagglutination of antibodies with different specificity to human collagen.
    Steffen C; Dichtl M; Knapp W; Brunner H
    Immunology; 1971 Oct; 21(4):649-57. PubMed ID: 4941375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.